vs
Side-by-side financial comparison of Axe Compute Inc. (AGPU) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $8.7K, roughly 20855.4× Axe Compute Inc.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -1740028.0%, a 1740027.2% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -1.3%). Over the past eight quarters, Axe Compute Inc.'s revenue compounded faster (33.6% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AGPU vs AVNS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $8.7K | $180.9M |
| Net Profit | $-150.9M | $-1.3M |
| Gross Margin | — | 47.5% |
| Operating Margin | -1990880.1% | 1.4% |
| Net Margin | -1740028.0% | -0.7% |
| Revenue YoY | -1.3% | 0.7% |
| Net Profit YoY | -6856.6% | 99.7% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.7K | $180.9M | ||
| Q3 25 | $3.6K | $177.8M | ||
| Q2 25 | $2.7K | $175.0M | ||
| Q1 25 | $110.3K | $167.5M | ||
| Q4 24 | $8.8K | $179.6M | ||
| Q3 24 | $3.9K | $170.4M | ||
| Q2 24 | $67.3K | $171.7M | ||
| Q1 24 | $4.9K | $166.1M |
| Q4 25 | $-150.9M | $-1.3M | ||
| Q3 25 | $-77.7M | $-1.4M | ||
| Q2 25 | $-2.1M | $-76.8M | ||
| Q1 25 | $-2.4M | $6.6M | ||
| Q4 24 | $-2.2M | $-397.3M | ||
| Q3 24 | $-3.1M | $4.3M | ||
| Q2 24 | $-3.2M | $1.8M | ||
| Q1 24 | $-4.2M | $-900.0K |
| Q4 25 | — | 47.5% | ||
| Q3 25 | -131.0% | 48.4% | ||
| Q2 25 | -579.4% | 52.6% | ||
| Q1 25 | 59.1% | 53.6% | ||
| Q4 24 | -250.5% | 54.6% | ||
| Q3 24 | -186.1% | 54.5% | ||
| Q2 24 | 79.4% | 55.7% | ||
| Q1 24 | -361.8% | 57.1% |
| Q4 25 | -1990880.1% | 1.4% | ||
| Q3 25 | -90654.1% | 0.1% | ||
| Q2 25 | -99174.8% | -42.6% | ||
| Q1 25 | -2073.3% | 6.1% | ||
| Q4 24 | -23848.9% | -233.0% | ||
| Q3 24 | -55296.7% | 7.0% | ||
| Q2 24 | -3664.6% | 3.7% | ||
| Q1 24 | -73734.7% | 2.4% |
| Q4 25 | -1740028.0% | -0.7% | ||
| Q3 25 | -2146264.3% | -0.8% | ||
| Q2 25 | -77198.4% | -43.9% | ||
| Q1 25 | -2214.6% | 3.9% | ||
| Q4 24 | -24676.9% | -221.2% | ||
| Q3 24 | -79208.9% | 2.5% | ||
| Q2 24 | -4730.1% | 1.0% | ||
| Q1 24 | -86843.2% | -0.5% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-1.66 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $-8.64 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $0.04 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.8M | $89.8M |
| Total DebtLower is stronger | — | $90.3M |
| Stockholders' EquityBook value | $47.7M | $778.2M |
| Total Assets | $52.9M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.8M | $89.8M | ||
| Q3 25 | $181.7K | $70.5M | ||
| Q2 25 | $506.1K | $90.3M | ||
| Q1 25 | $3.1M | $97.0M | ||
| Q4 24 | $611.8K | $107.7M | ||
| Q3 24 | $3.1M | $89.0M | ||
| Q2 24 | $5.3M | $92.2M | ||
| Q1 24 | $5.2M | $75.8M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $47.7M | $778.2M | ||
| Q3 25 | $-77.4M | $778.0M | ||
| Q2 25 | $-1.7M | $776.3M | ||
| Q1 25 | $-145.8K | $839.4M | ||
| Q4 24 | $-202.6K | $828.5M | ||
| Q3 24 | $2.0M | $1.2B | ||
| Q2 24 | $4.1M | $1.2B | ||
| Q1 24 | $4.1M | $1.2B |
| Q4 25 | $52.9M | $1.1B | ||
| Q3 25 | $3.1M | $1.1B | ||
| Q2 25 | $3.4M | $1.0B | ||
| Q1 25 | $5.9M | $1.1B | ||
| Q4 24 | $5.0M | $1.2B | ||
| Q3 24 | $7.5M | $1.7B | ||
| Q2 24 | $10.6M | $1.7B | ||
| Q1 24 | $10.6M | $1.7B |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.9M | $28.2M |
| Free Cash FlowOCF − Capex | — | $21.3M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | 0.0% | 3.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.9M | $28.2M | ||
| Q3 25 | $-1.7M | $14.0M | ||
| Q2 25 | $-3.3M | $6.8M | ||
| Q1 25 | $-985.8K | $25.7M | ||
| Q4 24 | $-2.1M | $57.9M | ||
| Q3 24 | $-2.5M | $23.0M | ||
| Q2 24 | $-3.2M | $27.8M | ||
| Q1 24 | $-3.4M | $-8.0M |
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | $-2.1M | $53.1M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $21.9M | ||
| Q1 24 | $-3.4M | $-12.1M |
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | -2.4% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | -23429.1% | 29.6% | ||
| Q3 24 | — | 11.7% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | -70379.8% | -7.3% |
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 6.3% | ||
| Q1 25 | 0.0% | 4.0% | ||
| Q4 24 | 73.7% | 2.7% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 3.4% | ||
| Q1 24 | 62.4% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.89× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.35× | ||
| Q2 24 | — | 15.44× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGPU
Segment breakdown not available.
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
